InspireMD Receives Russian Approval For CGuard Embolic Prevention System

InspireMD said Monday it has received regulatory approval to commercialize CGuard Embolic Prevention System (EPS) for the treatment of carotid artery disease by Russia’s Federal Service for Surveillance in Healthcare.
Among all European countries, Russia has the highest rate of mortality from cerebrovascular disease.

The CGuard EPS is designed to prevent peri-procedural and late embolization by trapping potential emboli against the arterial wall while maintaining perfusion to the external carotid artery. It is not approved for use in the U.S. Shares of the medical device company were trading 9% higher.

Leave a Comment